Roche completed the acquisition of an 83% stake in GenMark for $1.8bn.

Roche, a pharmaceuticals and diagnostics company, completed the acquisition of an 83% stake in GenMark, a provider of multiplex molecular diagnostic solutions, for $1.8bn. “The addition of GenMark Diagnostics’ proprietary multiplex technology, which is designed to detect multiple pathogens from a single patient sample, will broaden our best-in-class molecular diagnostics portfolio to help make lifesaving information available to healthcare providers quickly to improve patient outcomes," Thomas Schinecker, Roche Diagnostics CEO.